Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings

We initiated a randomized, placebo-controlled, phase 1/2 trial to evaluate the safety and immunogenicity of the S-268019-b recombinant protein vaccine, scheduled as 2 intramuscular injections given 21 days apart, in 60 randomized healthy Japanese adults. We evaluated 2 regimens of the S-910823 antig...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwata, Satoshi, Sonoyama, Takuhiro, Kamitani, Akari, Shibata, Risa, Homma, Tomoyuki, Omoto, Shinya, Igarashi, Kenji, Ariyasu, Mari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122779/
https://www.ncbi.nlm.nih.gov/pubmed/35606235
http://dx.doi.org/10.1016/j.vaccine.2022.04.054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122779/
https://www.ncbi.nlm.nih.gov/pubmed/35606235
http://dx.doi.org/10.1016/j.vaccine.2022.04.054

Ejemplares similares